Daratumumab Maintenance Improves Survival and Depth of Response in Multiple MyelomaRifkin, Robert M.Journal of Oncology Navigation & Survivorship
(Darzalex) followed by autologous stem cell transplant (ASCT) and daratumumab, bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) consolidation and daratumumab/lenalidomide maintenance in newly diagnosed, transplant-eligible multiple myeloma significantly improved progression-free survival...
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. PMID: 34529931 Daratumumab:...
Rifkin RM, Melear J, Faber E, et al. Daratumumab (DARA) Maintenance Therapy Following DARA + Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): End-of-Study Analysis of LYRA. Presented at: 2021 European Hematology Association Annual M...
During maintenance, 1800 mg of daratumumab was given once every 4 weeks in combination with 10 mg of lenalidomide per day. The primary end point was PFS. Key secondary end points were a complete response or better and minimal residual disease (MRD)–negative status. Findings from the trial,...
2. Moreau P, Hulin C, Perrot A, et al: Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagno...
by Elana Gotkine For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone induction and consolidation therapy and with lenalidomide maintenance therapy (D-VRd) improves progression-free survival...
If patients are deemed transplant-ineligible, they will undergo a period of extended induction therapy followed by maintenance, according to Bhutani. “As the therapeutic landscape of multiple myeloma grows every year, a greater proportion of patients are able to achieve stringent complete responses (...
Multiple myeloma is a proliferative disorder of plasma cells in the bone marrow with excessive monoclonal protein production. Despite the evolution of multiple drugs and management strategies including maintenance and autologous stem cell transplantation, the long-term results still remain undesirable. Those...
(DR) maintenance significantly improved progression-free survival (PFS) vs VRd induction, ASCT, VRd consolidation, and lenalidomide maintenance in patients with newly diagnosed, transplant-eligible multiple myeloma, according to primary findings from the phase 3 PERSEUS trial (NCT03710603) ...